Stockreport

IMNN: Results from OVATION 2 Study in Mid-2024… [Yahoo! Finance]

Imunon, Inc.  (IMNN) 
PDF Imunon, Inc. (NASDAQ:IMNN) is currently conducting the Phase 1/2 OVATION 2 trial of IMNN-001, the company's IL-12 gene-mediated immunotherapy that is based on the Thera [Read more]